2015, Number 4
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2015; 53 (4)
Renal cell carcinoma: pathological prognostic factors, staging and histopathological classification of 355 cases
Acosta-Jiménez E, Jerónimo-Guerrero D, Macías-Clavijo MÁ, Rivera-Diez D, Hernández-Briseño L, Beltrán-Suárez E, Martínez-Olivares J, Ángeles-Garay U
Language: Spanish
References: 22
Page: 454-465
PDF size: 699.20 Kb.
ABSTRACT
Background: New morphologic entities for Renal Cell Carcinoma (RCC)
that infl uence the prognosis have been described. Clinical staging has
also undergone several modifi cations, the last one published in 2010
7th edition of the American Joint Committee on Cancer. The aim of this
article is to determine the prevalence of histological subtypes, Fuhrman
grading and clinical staging of renal cell carcinomas.
Methods: This is a retrospective, descriptive and comparative study,
from January 2008 to June 2013. 355 cases of RCC were reclassifi ed
according to nuclear grading and new histopathological diagnostics and
staging according to the TNM. A Kappa index was used for the diagnostic
concordance and nuclear grading.
Results: Conventional renal cell carcinoma corresponded to 84.51 %, followed
by chromophobe carcinoma and papillary. Less common subtypes
were: multilocular cystic carcinoma, papillary clear cell carcinoma and others.
Nuclear grading was directly related to the tumoral size and clinical
staging (p < 0.001). The predominant stage was pT1b N0 M0, followed
by pT3a N0 M0.
Conclusions: The most frequent tumor was clear cell RCC, followed
by chromophobe carcinoma and papillary carcinoma. Nuclear grading,
necrosis, eosinophilic cells areas with areas of sarcomatoid and rhabdoid
differentiation are prognostic factors associated with an increased
aggression and risk of metastases.
REFERENCES
Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma perspectives of primary prevention World J Urol 2010;28(3):247- 52.
Parkin DM, Pisan P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54 (4):594-606.
DeCastro GJ, McKiernan MJ. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am. 2008; 35(4):581-592.
Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali A, Montironi R. 2009 update on the classifi cation of renal epitelial tumors in adults. Int J Urol. 2009;16(5):432–443.
López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO Classifi cation of The Renal Tumors of the Adults. Eur Urol. 2006;49(5):798-805.
Nagashima Y, Kuroda N, Yao M. Transition of Organizational Category on Renal Cancer. Jpn J Clin Oncol. 2013;43(3):233-242.
Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi. Current pathology keys of renal cell carcinoma. Eur Urol 2011; 60 (4):634-644.
Srigley J R, Delahunt B, Eble J N, Egevad L, Epstein J I, Grignon D. et al. The International Society of Urological Pathology (ISUP) Vancouver Classifi cation of Renal Neoplasia. Am J Surg Pathol. 2013;37(10):1469-1489.
López IJ. Carcinomas renales de células claras, papilar e híbridos. Criterios morfológicos, genéticos y difi cultades diagnósticas en la práctica diaria. Rev Esp Patol. 2007;40(3):161-170.
Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009;22(1):24-36.
Zantana RZ, Urdiales OA, Camarena RH, Fulda GS, Pérez BR, Merayo CC, et. al. Cáncer de células renales, factores patológicos pronósticos y nuevas estrategias de estadifi cación. Rev Mex Urol 2011;71 (4):218-224.
Klatte T, Anterasian C, Said JW, Martino M, Kabbinavar FF, Belldegrun AS, et al. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol. 2010;183(3):2143-2147.
Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan, Delahunt B. Nuclear grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol. 2006;30(9):1091-1096.
Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, et. al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol. 2010;34(9):1233-40.
Ljungberg B, Cowan NC, Handbury DC, Hora M, Kuczyk MA, Mersenburger AS. EAU Guidelines on Renal Cell Carcinoma: The 2010 update. Eur Urol 2010;58(3):398-406.
Jalón MA, Álvarez MM, Fernández GJM, Martín BJL, Martínez GF, García RJ et. al. Adenocarcinoma de células renales factores pronósticos y estadifi cación. Arch. Esp. Urol 2007;60(2):125-136.
Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC. Lohse C, Allmer C. Independient Validation of the 2010 American Joint Comittee on Cancer TNM Clasiffi cation For Renal Cell Carcinoma: Result From a Large Single Institution Cohort. J Urol 2011;185(6):2035-2039.
Pattard J J, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. J Clin Oncol 2005;23(12):2763-2771.
Amin MB, Tamboli P, Javidan J. Stricker Hans, De Peralta VM, Deshpande A et. al. Prognostic impact of histologic subtyping of adult renal epitelial neoplasm: and experience of 405 cases. Am J Surg Pathol 2002;26(3):281-91.
Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of the primary tumor patients with renal cell carcinoma. Cancer. 2005;103(12):2517-2525.
Sengupta, S., Lohse, C. M., Leibovich, B. C., Frank, I., Thompson, R. H., Webster, W. S., et. Al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer, 2005;104(3):511-520.
Srigley J R, Amin MB, Delahunt B, Campbell SC, Chang A, Grignon DJ.et. al. Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. Arch Pathol Lab Med. 2010;134(4):25-30.